Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by FactFinder1994on Nov 27, 2015 1:59pm
213 Views
Post# 24332366

Beyond life or death

Beyond life or death There are all the patients that are fortunate enough to make it through a sepsis experience but still face a difficult road ahead.  The ones who in the future will quickly receive our treatment and who benefit from a less severe and shorter time in ICU will also be less taxing on our health care systems.  Vital organs benefit when the duration and severity of stress or dysfunction is minimized thus providing a better quality of life after sepsis for those fortunate enough to get the best care.   We tend to focus on the most severe cases as that is where the differences (life or death) are most noticeable, however we should not overlook or forget about the benefits that go beyond life or death.  The EAA plays a key role in identifying and selecting those that will be most responsive to receiving PMX column treatment for endotoxin removal.  Being able to provide a more personalized approach to patients is an important step forward and Big Data will play an important role too.  
Bullboard Posts